Immediate Impact

6 from Science/Nature 63 standout
Sub-graph 1 of 23

Citing Papers

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy
2024 Standout
2 intermediate papers

Works of Sarah Paul being referenced

Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.
2018
Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)
2017

Author Peers

Author Last Decade Papers Cites
Sarah Paul 119 167 137 224 18 522
Amir Aghajanian 63 65 74 128 15 610
Atsushi Kaibara 72 69 63 134 22 522
Elisabetta Trevellin 46 76 40 229 21 533
Beatriz Morancho 75 183 38 140 19 628
Emma L. Shepherd 55 58 43 95 24 612
Qian Zhao 50 81 106 113 23 479
Ting Huang 37 117 73 143 31 586
Mads Malik Aagaard 84 78 18 192 20 566
Ju Hee Lee 40 62 52 259 17 560
Byung‐Hyun Park 38 70 60 97 15 525

All Works

Loading papers...

Rankless by CCL
2026